Description
Uncompromising Quality Control
At Clear Peptides, quality is verified through independent third-party analytical testing conducted on each production batch. Every peptide is supplied with lot-specific Certificates of Analysis (COAs) confirming identity, purity, and batch consistency.
All materials undergo RP-HPLC purity analysis and ESI-MS identity confirmation before release. No lot ships without passing both tests.
Quality Comparison
| Feature / Testing Standard | Clear Peptides | Other Labs (Avg.) |
|---|---|---|
| Standard COA (Qualitative & Quantitative) | ✔ Included with every lot | ✘ Often incomplete |
| RP-HPLC Purity Analysis | ✔ Every batch, ≥98% criterion | ✘ Inconsistently performed |
| ESI-MS Identity Confirmation | ✔ Every batch | ✘ Rarely provided |
| Lot-Specific Documentation | ✔ Permanently archived, retrievable | ✘ Often unavailable |
| US-Based Fulfillment | ✔ FedEx 2-Day cold-chain | ✘ Variable |
Thymosin Alpha-1 — Research Overview
Thymosin Alpha-1 (Tα1; thymalfasin) is a 28-amino acid peptide originally isolated from thymic tissue. It has been extensively studied as an immunological research compound for its interactions with pattern recognition receptor signaling, dendritic cell maturation, and T-lymphocyte activation pathways.
Research describes Tα1’s interactions with Toll-like receptors (TLR2, TLR9) and downstream NF-κB and MyD88-dependent signaling pathways, making it a well-characterized reference compound for innate immune signaling research.
Research Context Reported in Scientific Literature
Thymosin Alpha-1 has been evaluated in laboratory environments as described in peer-reviewed publications. Observations below are from controlled preclinical research models and do not constitute clinical evidence.
- Toll-like receptor pathway research: TLR2 and TLR9 signaling pathway activation, MyD88-dependent cascades, and innate immune response characterization
- Dendritic cell maturation: DC surface marker expression, cytokine secretion profiles, and antigen presentation pathway research
- T-lymphocyte activation: CD4+ and CD8+ T-cell activation pathway modulation and cytokine expression pattern studies
- NF-κB signaling cascade: Nuclear factor-kappa B pathway activation kinetics and downstream inflammatory gene expression research
- Immunomodulatory peptide pharmacology: Comparison with other thymic peptides (TB4, Thymosin β-10) in matched immunological research systems
These observations are exploratory and not conclusive.
Format & Handling
Supplied in sterile laboratory glass vials containing lyophilized peptide material. Reconstitution with bacteriostatic water or an appropriate laboratory solvent is required prior to research use.
Handling and storage should follow institutional laboratory protocols to maintain stability, purity, and analytical integrity. Store sealed vials at −20°C, protected from light and moisture.
Frequently Asked Questions
🚚 How fast is shipping?
Orders placed before 2PM PST ship same day via FedEx 2-Day with cold-chain packaging. Most orders arrive within 2 business days.
📦 When will I receive my tracking number?
Tracking is emailed immediately upon dispatch, typically within 24 hours of order placement.
🧪 How do you verify purity and quality?
Every lot undergoes independent third-party RP-HPLC purity analysis and ESI-MS identity confirmation. Lot-specific COAs are available via our COA Lookup tool.
💳 What payment methods do you accept?
We accept major credit cards via our secure Bankful payment gateway. All transactions are encrypted and processed securely.
↩️ What is your refund policy?
All sales are final unless the issue results from a verified error or quality failure on our part. See our Refund Policy for full details.
❄️ How should I store this product?
Lyophilized powder should be stored at −20°C in a sealed, desiccated container protected from light. Avoid repeated temperature cycling. After reconstitution, store at 2–8°C and use within 72 hours.
Intended Use: Research use only. Not for human consumption, medical, veterinary, or diagnostic use. Research findings are preliminary and do not imply safety or efficacy.
